Mutant Allele of CD44 (rs8193C>T) and Pum2 Regulatory Element as A Prognosis Factor of Prostate Neoplasms: A Case-Control and In Silico Studies

Document Type : Original Article


1 Department of Molecular and Cell Biology, Faculty of Science, University of Mazandaran, Babolsar, Iran

2 Department of Urology, Babol University of Medical Sciences, Babol, Iran


Expression of CD44 variant 6 (CD44v6) as a homing-associated cell adhesion molecule (HCAM), has
proved to change most cancer cells. Aim of the study is the effect of mutant allele of CD44 (rs8193C>T) and Pum2
regulatory element as a prognosis factor of prostate neoplasms: a case-control and in silico studies in the Mazandaran

Materials and Methods
In a case-control study, CD44-rs8193C>T genotyping of the 420 prostate neoplasms (210
benign prostatic hyperplasia (BPH) patients and 210 prostate cancer patients) and 150 healthy samples are performed
by the touchdown polymerase chain reaction with confronting two-pair primers (PCR-CTPP) method. The T mutant
allele effects on the mRNA structure and cell pathways were also investigated in silico methods.

Our results showed that the increase of T mutant allele frequency was significantly associated with BPH
compared with prostate cancer. Furthermore, results showed TT genotype was significantly associated with BPH
[odds ratio (OR)=0.572 and P=0.015], and also influenced the CD44v6 transcript secondary structure, miRNA binding,
and regulatory element-binding site for Pum2 protein. Attachment of Pum2 to standard CD44 transcript may lead to
transcript isoform-switching and shift-expression to a variety of CD44 isoforms, which can trigger some of the cell
signaling pathways, such as Nanog-Stat, PKC-Nanog, and PKC-Twist.

Based on this, the presence of the T mutant allele of CD44 (rs8193C>T) in the populations may create
a regulatory element-binding site for Pum2. So, it could be known as a prognosis factor and prediction of prostate
neoplasms. However, more comprehensive studies in different populations (with various ethnicities and large population
sizes), and also CD44v6 gene expression studies in protein and transcript levels are required to confirm our data.


1. Miah S, Catto J. BPH and prostate cancer risk. Indian J Urol. 2014; 30(2): 214-218.
2. Rawla, P. Epidemiology of prostate cancer. World J Oncol. 2019; 10(2): 63.
3. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998; 396 (6712): 643-649.
4. Wiklund F, Jonsson BA, Brookes AJ, Strömqvist L, Adolfsson J,Emanuelsson M, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res. 2004; 10(21): 7150-7156.
5. Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, Spurdle AB, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis. 2007; 28(5): 1032-1039.
6. Chen R, Ren S, Sun Y. Genome-wide association studies on prostate cancer: the end or the beginning? Protein Cell. 2013; 4(9): 677-686.
7. Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate. 2014; 74(6): 602-617.
8. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. J Mol Pathol. 1999; 52(4): 189-96.
9. Gallatin WM, Wayner EA, Hoffman PA, St John T, Butcher EC, Carter WG, et al. Structural homology between lymphocyte receptors for high endothelium and class III extracellular matrix receptor. Proc Natl Acad Sci. 1989; 86(12): 4654-4658.
10. Heldin P, Kolliopoulos C, Lin CY, Heldin, CH. Involvement of hyaluronan and CD44 in cancer and viral infections. Cell Signal. 2020; 65: 109427.
11. Bellerby R, Smith C, Kyme S, Gee J, Günthert U, Green A, et al. Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Front Oncol. 2016; 6: 145.
12. Knutson JR, Iida J, Fields GB, McCarthy JB. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement
membranes. Mol Biol Cell. 1996; 7(3): 383-396.
13. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Hauβmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991; 65(1): 13-24.
14. Wang Q, Teder P, Judd NP, Noble PW, Doerschuk CM. CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Am J Pathol. 2002; 161(6): 2219-2228.
15. Jordan AR, Racine RR, Hennig MJ, Lokeshwar VB. The role of CD44 in disease pathophysiology and targeted treatment. Front Immunol. 2015; 6: 182.
16. Estess P, DeGrendele HC, Pascual V, Siegelman MH. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J Clin Invest. 1998; 102(6): 1173- 1182.
17. Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB. Expression of CD44 3′-untranslated region regulates endogenous micro- RNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res. 2011; 39(8): 3026-3041.
18. Noordzij MA, Van Steenbrugge GJ, Verkaik NS, Schröder FH, Van der kwast T. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res. 1997; 3(5): 805-815.
19. Heider KH, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann E, et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother. 1996; 43(4): 245-253.
20. Heider KH, Kuthan H, Stehle G, Munzer G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother. 2004; 53(7): 567-579.
21. Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal. 2014; 26(10): 2234-2239.
22. Rutnam ZJ, Yang BB. The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci. 2012; 125(8): 2075-2085.
23. Verma A, Kapoor R, Mittal RD. Cluster of differentiation 44 (CD44) gene variants: a putative cancer stem cell marker in risk prediction of bladder cancer in north indian population. Indian J Clin Biochem. 2017; 32(1): 74-83.
24. Liu Y, Qing H, Su X, Wang C, Li Z, Liu S. Association of CD44 gene polymorphism with survival of NSCLC and risk of bone metastasis. Med Sci Monit. 2015; 21: 2694-2700.
25. Mokhtarian R, Tabatabaeian H, Saadatmand P, Azadeh M, Balmeh N, Yakhchali B, et al. CD44 gene rs8193 c allele is significantly enriched in gastric cancer patients. Cell J. 2020; 21(4): 451-458.
26. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3th ed. New York: Cold Spring Harbor Laboratory; 2013.
27. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011; 17(21): 6934-6943.
28. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, et al. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. Annal Oncol. 2015; 26(8): 1728-1733.
29. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res. 2008; 36(Database issue): D820-D824.
30. Wu X, He X, Li S, Xu X, Chen X, Zhu H. Long non-coding RNA ucoo2kmd. 1 regulates CD44-dependent cell growth by competing for miR-211-3p in colorectal cancer. PLoS One. 2016; 11(3): e0151287.
31. Winder T, Ning Y, Yang D, Zhang W, Power DG, Bohanes P, et al. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer. 2011; 129(5): 1096-1104.
32. Lin X, You X, Cao X, Pan S. Association of single-nucleotide polymorphisms of CD44 gene with susceptibility to breast cancer in Chinese women. Med Sci Monit. 2018; 24: 3077-3083.
33. Deng Y, Chen ZJ, Lan F, He QT, Chen SY, Du YF, et al. Association of CD44 polymorphisms and susceptibility to HBV related hepatocellular carcinoma in the Chinese population. J Clin Lab Anal. 2019; 33(8): e22977.
34. Skeeles LE, Fleming JL, Mahler KL, Toland AE. The impact of 3′ UTR variants on differential expression of candidate cancer susceptibility genes. PLoS One. 2013; 8(3): e58609.
35. Capowski EE, Esnault S, Bhattacharya S, Malter JS. Y box-binding factor promotes eosinophil survival by stabilizing granulocytemacrophage colony-stimulating factor mRNA. J Immunol. 2001; 167(10): 5970-5976.
36. Chen X, Li A, Sun BF, Yang Y, Han YN, Yuan X, et al. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019; 21(8): 978-990.
37. Van Etten J, Schagat TL, Hrit J, Weidmann CA, Brumbaugh J, Coon JJ, et al. Human Pumilio proteins recruit multiple deadenylases to efficiently repress messenger RNAs. J Biol Chem. 2012; 287(43): 36370-36383.
38. Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF Jr, et al. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 1999; 59(10): 2329-2331.
39. Moura CM, Pontes J Jr, Reis ST, Viana NI, Morais DR, Dip N, et al. Expression profile of standard and variants forms of CD44 related to prostate cancer behavior. Int J Biol Markers. 2015; 30(1): e49-55.
40. Di Stefano C, Grazioli P, Fontanella RA, De Cesaris P, D’Amore A, Regno M, et al. Stem-like and highly invasive prostate cancer cells expressing CD44v8-10 marker originate from CD44-negative cells. Oncotarget. 2018; 9(56): 30905-30918.